Foghorn Therapeutics Reports Q1 2026 Financial Results

What Happened

• Foghorn Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026 in a press release dated May 7, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release (Exhibit 99.1).
• The company also furnished an investor presentation dated May 2026 under Regulation FD (Item 7.01) to be used in meetings and presentations with investors (Exhibit 99.2).

Key Details

• Date of 8-K filing and press release: May 7, 2026.
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Exhibits furnished: Exhibit 99.1 (press release) and Exhibit 99.2 (investor presentation, May 2026).
• Disclosure types reported: Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD investor materials).

Why It Matters

• The filing delivers the company’s latest quarterly results and related investor materials, which provide timely information on Foghorn’s financial performance and business progress.
• Investors and analysts use the press release and presentation to assess recent results, revenue/earnings trends, and management commentary; those materials can influence trading decisions and valuations once reviewed.